Incyte Corporation


Stock Update (NASDAQ:INCY): Incyte Corporation Announces 3Q:16 Financial Results and Updates Key Clinical Programs

Incyte Corporation (NASDAQ:INCY) reports 2016 third-quarter financial results, including strong revenue growth driven by increased sales of Jakafi® (ruxolitinib) in the U.S.

Incyte Corporation (INCY) Epacadostat and Keytruda Could Be Best in Class Immuno-Oncology Combination: Top Analyst

At the European Society for Medical Oncology (ESMO) conference, Incyte Corporation (NASDAQ:INCY) presented updated data from its Phase I trial of epacadostat and …

Stock Update (NASDAQ:INCY): Incyte Corporation Presents Updated Data from Epacadostat at ESMO 2016

Incyte Corporation (NASDAQ:INCY) announced that updated data from the Phase I portion of the ECHO-202 trial evaluating the safety and efficacy of epacadostat, …

Stock Update (NASDAQ:INCY): Incyte Corporation Announces ESMO Publication of Updated Phase 1 Data in Advanced Melanoma

Incyte Corporation (NASDAQ:INCY) announced that the European Society for Medical Oncology (ESMO) has published an abstract (#1110PD) containing updated data from the Phase 1 …

Healthcare Analysts Change Price Targets on Array Biopharma Inc (ARRY) and Incyte Corporation (INCY)

Array Biopharma Inc Leerink’s top analyst Michael Schmidt was out today with a favorable report on shares of Array Biopharma Inc (NASDAQ:ARRY), raising the …

Company Update (NASDAQ:INCY): Incyte Corporation Announces First Patient Treated in ECHO-301 Phase 3 Study

Incyte Corporation (NASDAQ:INCY) announced that the first patient has been treated in the ECHO-301 study—a Phase 3 trial evaluating epacadostat, Incyte’s investigational, highly …

Healthcare Analysts Weigh In on Gilead Sciences, Inc. (GILD) and Incyte Corporation (INCY) Following Management Meetings

Analysts were able to meet with management from Gilead Sciences, Inc. (NASDAQ:GILD) and Incyte Corporation (NASDAQ:INCY) to gain insight into both companies’ future plans.

Stock Update (NASDAQ:INCY): Incyte Corporation Announces New Phase 3 Data From PV Drug Study

Incyte Corporation (NASDAQ:INCY) announced new 28-week data from the Phase 3 RESPONSE-2 study of Jakafi® (ruxolitinib). The data show that Jakafi was superior to …

BMO Chimes In on Healthcare Giants: Valeant Pharmaceuticals Intl Inc (VRX), Celgene Corporation (CELG), Incyte Corporation (INCY)

Analysts from sell-side firm BMO Capital weigh in on three healthcare giants. While one remains on the sidelines of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) following …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts